Join us for an insightful presentation exploring the latest, practice-changing clinical trials that are reshaping the standards of care in breast cancer radiotherapy. This session will spotlight the integration of advanced radiotherapy techniques, particularly stereotactic body radiotherapy (SBRT) using the CyberKnife® System and their emerging roles in both localized and metastatic breast cancer.
Through real-world clinical case discussions, we’ll illustrate how these innovations are being applied in practice, offering attendees a practical and evidence-informed perspective on evolving treatment paradigms.
Learning Objectives
By the end of this webinar, participants will be able to:
- Summarize the most recent clinical trials and updated recommendations influencing breast cancer radiotherapy.
- Evaluate the clinical indications, advantages, and limitations of incorporating stereotactic body radiotherapy into current treatment strategies.
- Apply evidence-based, guideline-aligned approaches to clinical decision-making, supported by real-world case examples.
This webinar is pending approval by CAMPEP for 1 MPCEC hour and approved by ASRT for 1 category A credit.
Presenter: Syrine Ben Dhia, M.D.
Radiation Oncologist, Antoine Lacassagne Center, Nice, France
Dr. Syrine Ben Dhia is a radiation oncologist with over five years of clinical experience, including the past two years at the Antoine Lacassagne Center in Nice. Her expertise spans the treatment of breast, sarcoma and gastrointestinal cancers. She is deeply committed to therapeutic innovation and actively involved in clinical research, with a strong focus on advancing patient-centred care and improving outcomes through cutting-edge radiotherapy techniques.
Radiation Oncologist, National Institute of Oncology, Budapest, Hungary
Norbert Mészáros, M.D., Ph.D. is a Senior Consultant at the National Institute of Oncology’s Department of Radiotherapy and an Assistant Professor at Semmelweis University, Hungary. With an M.D. from Semmelweis University and dual specializations in Radiotherapy and Clinical Oncology, Dr. Mészáros earned his Ph.D. from the University of Pécs in 2021. His clinical expertise spans comprehensive radiotherapy and radio-chemotherapy for both malignant and benign conditions. He has played a leading role in national and international clinical studies, particularly in breast cancer treatment, and serves as the Hungarian Principal Investigator for the GEC-ESTRO multicenter study on HDR interstitial accelerated radiotherapy. A dedicated educator, Dr. Mészáros teaches radiotherapy to Hungarian and English-speaking medical students and has supervised multiple award-winning theses. He also holds leadership roles as Treasurer of the Hungarian Society of Radiation Therapy and Quality Management Coordinator at Semmelweis University. His research focuses on breast cancer brachytherapy, IMRT, and radiation sensitivity in cervical cancer. Dr. Mészáros is a member of several oncology committees and professional societies, and has received multiple awards for his contributions to radiation oncology.
